Lymphomatoid papulosis during immune checkpoint inhibitor treatment

Int J Hematol. 2022 Aug;116(2):155-157. doi: 10.1007/s12185-022-03410-z. Epub 2022 Jun 20.

Authors

Rena Morita^{1

2}, Kiyoshi Kasai³

Affiliations

¹ Division of Fundamental Health Sciences, School of Nursing and Social Services, Health Sciences University of Hokkaido, Kanazawa 1757, Tobetsu, Hokkaido, 061-0293, Japan. r-mori@hoku-iryo-u.ac.jp.
² Department of Pathology, Otaru General Hospital, Otaru, Japan. r-mori@hoku-iryo-u.ac.jp.
³ Department of Pathology, Otaru General Hospital, Otaru, Japan.

PMID: 35723861
DOI: 10.1007/s12185-022-03410-z

No abstract available

Keywords: Immune checkpoint inhibitors; Lymphomatoid papulosis; Nivolumab.

MeSH terms

Hodgkin Disease*
Humans
Immune Checkpoint Inhibitors
Lymphomatoid Papulosis*
Skin
Skin Neoplasms*

Substances

Immune Checkpoint Inhibitors